Compare with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

KRSNAA DIAGNOSTICS vs KIMS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    KRSNAA DIAGNOSTICS KIMS KRSNAA DIAGNOSTICS/
KIMS
 
P/E (TTM) x - - - View Chart
P/BV x 9.7 12.4 77.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 KRSNAA DIAGNOSTICS   KIMS
EQUITY SHARE DATA
    KRSNAA DIAGNOSTICS
Mar-21
KIMS
Mar-21
KRSNAA DIAGNOSTICS/
KIMS
5-Yr Chart
Click to enlarge
High RsNANA-   
Low RsNANA-   
Sales per share (Unadj.) Rs998.8171.4 582.7%  
Earnings per share (Unadj.) Rs284.526.5 1,074.3%  
Cash flow per share (Unadj.) Rs342.135.4 965.2%  
Dividends per share (Unadj.) Rs00-  
Avg Dividend yield %NMNM- 
Book value per share (Unadj.) Rs355.5111.3 319.3%  
Shares outstanding (eoy) m6.5077.59 8.4%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x00-   
Avg P/E ratio x00-  
P/CF ratio (eoy) x00-  
Price / Book Value ratio x00-  
Dividend payout %00-   
Avg Mkt Cap Rs m00-   
No. of employees `000NANA-   
Total wages/salary Rs m2962,202 13.4%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m6,49213,299 48.8%  
Other income Rs m122102 120.4%   
Total revenues Rs m6,61513,401 49.4%   
Gross profit Rs m3,4663,757 92.2%  
Depreciation Rs m374695 53.8%   
Interest Rs m259373 69.5%   
Profit before tax Rs m2,9552,790 105.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,105735 150.3%   
Profit after tax Rs m1,8492,055 90.0%  
Gross profit margin %53.428.3 189.0%  
Effective tax rate %37.426.4 141.9%   
Net profit margin %28.515.5 184.4%  
BALANCE SHEET DATA
Current assets Rs m2,4814,512 55.0%   
Current liabilities Rs m1,8382,783 66.0%   
Net working cap to sales %9.913.0 76.2%  
Current ratio x1.41.6 83.3%  
Inventory Days Days2511 216.9%  
Debtors Days Days4130 135.2%  
Net fixed assets Rs m3,5649,820 36.3%   
Share capital Rs m2,489776 320.8%   
"Free" reserves Rs m-1787,861 -2.3%   
Net worth Rs m2,3108,637 26.7%   
Long term debt Rs m1,6801,846 91.0%   
Total assets Rs m6,04514,332 42.2%  
Interest coverage x12.48.5 146.2%   
Debt to equity ratio x0.70.2 340.1%  
Sales to assets ratio x1.10.9 115.7%   
Return on assets %34.916.9 205.9%  
Return on equity %80.023.8 336.5%  
Return on capital %80.530.2 266.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m00-   
Fx outflow Rs m00-   
Net fx Rs m00-   
CASH FLOW
From Operations Rs m1,0263,560 28.8%  
From Investments Rs m-611-3,542 17.3%  
From Financial Activity Rs m30898 314.1%  
Net Cashflow Rs m723116 622.1%  

Share Holding

Indian Promoters % 27.4 38.8 70.5%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 36.2 28.5 126.7%  
FIIs % 6.0 9.9 60.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 72.6 61.2 118.7%  
Shareholders   75,554 86,389 87.5%  
Pledged promoter(s) holding % 0.0 13.5 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare KRSNAA DIAGNOSTICS With:   INDRAPRASTHA MEDICAL  FORTIS HEALTHCARE  CHOKSI LAB.  MEDINOVA DIAG.  GIAN LIFE CARE  



Today's Market

5 Reasons Why Sensex Plunged 765 Points Today(Closing)

It was a volatile day for Indian share market today. After opening the day in green, benchmark indices erased gains within the first hour and kept falling as the session progressed.

Related Views on News

KIMS Shares Make Strong Debut Listing at a 22% Premium (Views On News)

Jun 28, 2021

KIMS shares pare gains after making a strong debut on the exchanges.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

6 Popular Stocks that Turned into Penny Stocks(Views On News)

Nov 27, 2021

A look at popular stocks that crashed big time and never recovered, i.e. which went from 'Multibaggers to Multibeggers'.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

5 Indian Companies Embracing Blockchain Technology(Views On News)

Nov 23, 2021

Blockchain adoption in India was slow in the past. Now, the technology is being well received.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

KRSNAA DIAGNOSTICS SHARE PRICE


Dec 3, 2021 (Close)

TRACK KRSNAA DIAGNOSTICS

  • Track your investment in KRSNAA DIAGNOSTICS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON KRSNAA DIAGNOSTICS

KRSNAA DIAGNOSTICS - INDRAPRASTHA MEDICAL COMPARISON

COMPARE KRSNAA DIAGNOSTICS WITH

MARKET STATS